Balyasny Asset Management
SGMO

Balyasny Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Balyasny Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Buy
+5,288,097
New +$2.1M ﹤0.01% 1966
2025
Q1 		– Sell
-136,687
Closed -$139K – 3233
2024
Q4 		$139K Buy
+136,687
New +$250K ﹤0.01% 2573
2024
Q3 		– Sell
-31,773
Closed -$11.4K – 3121
2024
Q2 		$11.4K Buy
+31,773
New +$17.2K ﹤0.01% 2490
2023
Q1 		– Sell
-21,355
Closed -$67.1K – 3098
2022
Q4 		$67.1K Buy
+21,355
New +$82.9K ﹤0.01% 2308
2022
Q3 		– Sell
-25,900
Closed -$107K – 3223
2022
Q2 		$107K Buy
25,900
+7,753
+43% +$33.5K ﹤0.01% 2273
2022
Q1 		$105K Buy
+18,147
New +$108K ﹤0.01% 2133
2020
Q2 		– Sell
-92,994
Closed -$592K – 1455
2020
Q1 		$592K Buy
92,994
+51,863
+126% +$385K 0.01% 867
2019
Q4 		$344K Buy
+41,131
New +$378K ﹤0.01% 1048
2019
Q3 		– Sell
-17,264
Closed -$186K – 1532
2019
Q2 		$186K Buy
+17,264
New +$184K ﹤0.01% 1403
2019
Q1 		– Sell
-25,806
Closed -$296K – 1630
2018
Q4 		$296K Buy
+25,806
New +$321K ﹤0.01% 1233
2017
Q4 		– Sell
-14,451
Closed -$217K – 2273
2017
Q3 		$217K Sell
14,451
-337,249
-96% -$3.73M ﹤0.01% 1672
2017
Q2 		$3.1M Buy
+351,700
New +$2.26M 0.01% 857
2016
Q2 		– Sell
-163,697
Closed -$990K – 1414
2016
Q1 		$990K Sell
163,697
-1,441,193
-90% -$8.65M 0.01% 773
2015
Q4 		$14.7M Buy
1,604,890
+1,527,638
+1,977% +$11.8M 0.1% 267
2015
Q3 		$436K Buy
+77,252
New +$637K ﹤0.01% 836
2015
Q1 		– Sell
-740,857
Closed -$11.3M – 1058
2014
Q4 		$11.3M Buy
740,857
+560,857
+312% +$6.81M 0.1% 274
2014
Q3 		$1.94M Buy
+180,000
New +$2.35M 0.02% 610
2014
Q2 		– Sell
-276,600
Closed -$5M – 761
2014
Q1 		$5M Buy
276,600
+77,135
+39% +$1.49M 0.06% 368
2013
Q4 		$2.77M Buy
+199,465
New +$2.3M 0.04% 379

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Balyasny Asset Management's SGMO Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026: 5,288,097 shares worth $1.31M. The stake represents ﹤0.01% of the portfolio and ranks #1966 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in SGMO as recently as Q4 2024.

Balyasny Asset Management first reported a position in SGMO in Q4 2013 and has held it in 19 quarters since. The position peaked at $14.7M in Q4 2015. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Balyasny Asset Management held 5,288,097 shares of SANGAMO THERAPEUTICS INC worth $1.31M as of Q1 2026.
  • SANGAMO THERAPEUTICS INC was a new Balyasny Asset Management position in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1966 holding.
  • Balyasny Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2013 and has held it in 19 quarters since.
  • Balyasny Asset Management's SANGAMO THERAPEUTICS INC position peaked at $14.7M in Q4 2015.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.